Pfizer Venture Investments

Portfolio Companies 2026 for Pfizer Venture Investments: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Pfizer Venture Investments accounts for 10 tracked companies with verified cap-table data, 10 of which disclose round sizes totalling $5.9B. The median disclosed raise is $325M, and the largest is Morphic Therapeutic at $3.2B, ahead of Nimbus Therapeutics ($600M) and ReCode Therapeutics ($570M).

The names that recur most often on these portfolio cap tables are Pfizer Venture Investments (10 companies), SR One (4 companies), Polaris Partners (2 companies), OrbiMed (2 companies), Osage University Partners (2 companies), Roche Venture Fund (2 companies). By latest disclosed round, the market skews Series B (4), Series A (3), IPO (1), Series C (1).

Best funded Pfizer Venture Investments companies

  1. Morphic Therapeutic — $3.2B (latest: Series B)
  2. Nimbus Therapeutics — $600M (latest: Series B)
  3. ReCode Therapeutics — $570M (latest: Series B)
  4. Merus — $500M (latest: IPO)
  5. Effector Therapeutics — $325M (latest: Series A)
  6. Imara — $250M (latest: Series B)
  7. Epic Sciences — $196M
  8. MISSION Therapeutics — $114M (latest: Series A)
  9. ENYO Pharma — $102M (latest: Series C)
  10. Petra Pharma — $48M (latest: Series A)

Pfizer Venture Investments — related firms and companies (53)

Pfizer Venture Investments alternatives · All research reports